A systemic review of PET and biology in lung cancer

American Journal of Translational Research

Volumn 3, Issue 4, 2011, Pages 383-391

  Kaira, Kyoichi ^a,b   Oriuchi, Noboru ^b   Sunaga, Noriaki ^b   Ishizuka, Tamotsu ^b   Shimizu, Kimihiro ^b   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG; Cell metabolism; Hypoxia; Lung cancer; Molecular biology; Molecular imaging; PET; Proliferation

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 ALPHA METHYLTYROSINE F 18; 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID ANTIBODY F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IODO ALPHA METHYL LEVO TYROSINE I 123; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; CANCER CELL CULTURE; DRUG ACCUMULATION; GLUCOSE METABOLISM; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MOLECULAR BIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SYSTEMATIC REVIEW;

EID: 80051735385     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen JA, Lerut TE, Mor-telmans LA, Demedts MG. Lymph node stag-ing in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16: 2142-9.
2. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tu-mours benefit oncology? Eur J Nucl Med 1997; 24: 691-705.
3. Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, Coleman RE. FDG-PET in differentiating lymphoma from nonma-lignant central nervous system lesions in pa-tients with AIDS. Nucl Med 1993; 34: 567-75.
4. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, Koh Y, Hanaoka H, Tominaga H, Oriuchi N, Kondo H, Nakajima T, Yamamoto N. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010; 28: 3746-53.
5. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, Seki H, Oguchi M, Taki S, Nambu Y, Tonami H, Katsuda S, Yamamoto I. Correlation of Glut-1 glucose transporter ex-pression with. Eur J Nucl Med 2000; 27: 1778-85.
6. Chung JH, Cho KJ, Lee SS, Baek HJ, Park JH, Cheon GJ, Choi CW, Lim SM. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18) F-FDG PET results in lung cancer staging. J Nucl Med 2004; 45: 999-1003.
7. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, Manabe T, Saga T. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and in-flammatory lesions of the lung. Neoplasia 2005; 7:369-79.
8. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E. Differential prognostic impact of hy-poxia induced and diffuse HIF-1alpha expres-sion in invasive breast cancer. J Clin Pathol 2005; 58: 172-7.
9. Elson DA, Ryan HE, Snow JW, Johnson R, Ar-beit JM. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcino-genesis and wound healing. Cancer Res 2000; 60:6189-95.
10. Elson DA, Ryan HE, Snow JW, Johnson R, Ar-beit JM. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcino-genesis and wound healing. Cancer Res 2000; 60: 6189-95.
11. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002; 35: 9-26.
12. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046-51.
13. 18F-FDG uptake on PET in pulmonary pleo-morphic carcinoma. Lung Cancer 2011; 71: 144-50.
14. Caracó C, Aloj L, Chen LY, Chou JY, Eckelman WC. Cellular release of [18F] 2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 2000; 275: 18489-94.
15. Kaira K, Oriuchi N, Otani Y, Yanagitani N, Su-naga N, Hisada T, Ishizuka T, Endo K, Mori M. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131: 1019-27.
16. Kaira K, Ohde Y, Okumura T, Nakagawa K, Takahashi T, Murakami H, Naito T, Tsuya A, Nakamura Y, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Relationship be-tween F-FDG uotake on PET and various bio-logic molecular markers in benign pulmonary lesion: comparison with primary lung cancer. Ann Nucl Med 2011 in press.
17. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-65.
18. Marom EM, Aloia TA, Moore MB, Hara M, Herndon JE 2nd, Harpole DH Jr, Goodman PC, Patz EF Jr. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 2001; 33: 99-107.
19. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F] fluorodeoxyglu-cose uptake with glucose transporter-1 ex-pression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004; 25: 11-7.
20. Chung JH, Cho KJ, Lee SS, Baek HJ, Park JH, Cheon GJ, Choi CW, Lim SM. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18) F-FDG PET results in lung cancer staging. J Nucl Med 2004; 45: 999-1003.
21. Chung JH, Lee WW, Park SY, Choe G, Sung SW, Chung JK, Lee MC, Kim SE. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. Eur J Surg Oncol 2006; 32: 989-95.
22. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC, Oyen WJ. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007; 55: 79-87.
23. Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK, So Y, Lee DS, Chung JK, Lee MC, Kim SE. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007; 62: 214-9.
24. Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Correlation Be-tween 18F-FDG Uptake on PET and Molecular Biology in Metastatic Pulmonary Tumors. J Nucl Med 2011; 52: 705-11.
25. Usuda K, Sagawa M, Aikawa H, Ueno M, Ta-naka M, Machida Y, Zhao XT, Ueda Y, Higashi K, Sakuma T. Correlation between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer. Gen Thorac Car-diovasc Surg. 2010; 58: 405-10.
26. Khandani AH, Whitney KD, Keller SM, Isasi CR, Donald Blaufox M. Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. Nucl Med Commun 2007; 28: 173-7.
27. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, De Ruysscher D. The maximum uptake of (18) F-deoxyglucose on positron emission tomography scan corre-lates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung can-cer. Eur J Cancer 2007; 43: 1392-8.
28. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neu-roendocrine tumors of the lung. Lung Cancer 2008; 61: 54-60.
29. Nguyen XC, So Y, Chung JH, Lee WW, Park SY, Kim SE. High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with re-spect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-D-glucose uptake. Eur J Cancer 2008; 44: 692-8.
30. Mees G, Vangestel C, Dierckx R, Pauwels P, Van Meerbeeck J, Van de Wiele C. Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer. Cancer Biother Radiopharm 2010; 25: 149-54.
31. Kim SJ, Hwang SH, Kim IJ, Lee MK, Lee CH, Lee SY, Lee EY. The association of 18F-deoxyglucose (FDG) uptake of PET with poly-morphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients. J Exp Clin Cancer Res 2010;29:69.
32. Márián T, Szabó G, Goda K, Nagy H, Szincsák N, Juhász I, Galuska L, Balkay L, Mikecz P, Trón L, Krasznai Z. In vivo and in vitro multi-tracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging 2003; 30: 1147-54.
33. Higashi K, Ueda Y, Ikeda R, Kodama Y, Guo J, Matsunari I, Oguchi M, Tonami H, Katsuda S, Yamamoto I. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. Nucl Med Commun 2004; 25: 19-27.
34. Sasaki M, Sugio K, Kuwabara Y, Koga H, Na-kagawa M, Chen T, Kaneko K, Hayashi K, Shioyama Y, Sakai S, Honda H. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. Ann Nucl Med 2003; 17: 189-96.
35. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neu-tral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-32.
36. Chairoungdua A, Segawa H, Kim JY, Miyamoto K, Haga H, Fukui Y, Mizoguchi K, Ito H, Takeda E, Endou H, Kanai Y. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycopro-tein. J Biol Chem 1999; 274: 28845-8.
37. Imai H, Kaira K, Oriuchi N, Shimizu K, Tomi-naga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yama-moto N, Mori M, Kanai Y. Inhibition of L-type amino acid transporter 1 has antitumor activ-ity in non-small cell lung cancer. Anticancer Res 2010; 30: 4819-28.
38. Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, Yang D. Synthesis of iso-mers of 18F-labelled amino acid radiopharma-ceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purifi-cation system. Nucl Med Commun 1997; 18: 169-75.
39. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Dobashi K, Kanai Y, Endou H, Na-kajima T, Endo K, Mori M. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007; 13: 6369-78.
40. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagi-tani N, Sunaga N, Hisada T, Tanaka S, Ishi-zuka T, Kanai Y, Endou H, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98: 742-8.
41. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagi-tani N, Sunaga N, Hisada T, Tanaka S, Ishi-zuka T, Kanai Y, Endou H, Nakajima T, Mori M. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008; 99: 2380-6.
42. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higu-chi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clini-copathological study. Int J Cancer 2009; 124: 1152-60.
43. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagi-tani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expres-sion in early stage squamous cell carcinoma of the lung. Cancer Sci 2009; 100: 248-54.
44. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higu-chi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 2009; 100: 753-8.
45. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagi-tani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 2009; 66: 120-6.
46. Imai H, Kaira K, Oriuchi N, Yanagitani N, Su-naga N, Ishizuka T, Kanai Y, Endou H, Naka-jima T, Mori M. L-type amino acid transporter 1 expression is a prognostic marker in pa-tients with surgically resected stage I non-small cell lung cancer. Histopathology 2009; 54: 804-13.
47. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagi-tani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol 2009; 16: 3473-81.
48. Kaira K, Oriuchi N, Shimizu K, Imai H, Tomi-naga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung can-cer. Nucl Med Biol 2010; 37: 911-6.
49. Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 2009; 50: 1770-6.
50. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagi-tani N, Sunaga N, Hisada T, Kawashima O, Iijima H, Ishizuka T, Kanai Y, Endou H, Naka-jima T, Mori M. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 2008; 204: 553-61.
51. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagi-tani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. L-type amino acid transporter 1 (LAT1) is frequently ex-pressed in thymic carcinomas but is absent in thymomas. J Surg Oncol 2009; 99: 433-8.
52. Yasukawa T, Yoshikawa K, Aoyagi H, Yama-moto N, Tamura K, Suzuki K, Tsujii H, Murata H, Sasaki Y, Fujisawa T. Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 2000; 41: 283-90.
53. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, Iwata R, Ido T. Differ-ential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-32.
54. Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004; 31: 1064-72.
55. Pauleit D, Floeth F, Tellmann L, Hamacher K, Hautzel H, Müller HW, Coenen HH, Langen KJ. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 2004; 45: 374-81.
56. Pauleit D, Stoffels G, Schaden W, Hamacher K, Bauer D, Tellmann L, Herzog H, Bröer S, Coenen HH, Langen KJ. PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. J Nucl Med 2005; 46: 411-6.
57. Jager PL, Groen HJ, van der Leest A, van Put-ten JW, Pieterman RM, de Vries EG, Piers DA. L-3-[123I] iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary obser-vations. J Nucl Med 2001; 42: 579-85.
58. Shikano N, Kanai Y, Kawai K, Inatomi J, Kim DK, Ishikawa N, Endou H. Isoform selectivity of 3-125I-iodo-alpha-methyl-L-tyrosine mem-brane transport in human L-type amino acid transporters. J Nucl Med 2003; 44: 244-6.
59. Nye JA, Schuster DM, Yu W, Camp VM, Good-man MM, Votaw JR. Biodistribution and radia-tion dosimetry of the synthetic nonmetabo-lized amino acid analogue anti-18F-FACBC in humans. J Nucl Med 2007; 48: 1017-20.
60. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-49.
61. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003; 195: 1-16.
62. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ; Trans-Tasman Radia-tion Oncology Group Study 98.02. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck can-cer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006; 24: 2098-104.
63. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemi-carbazone) positron emission tomography: Comparative study featuring microPET imag-ing, Po2 probe measurement, autoradiogra-phy, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005; 61: 1493-502.
64. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30: 844-50.
65. Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, Saun-der TH, O'Keefe GJ, Scott AM. Lack of correla-tion of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisoni-dazole and 18F-FDG PET. J Nucl Med 2006; 47: 1921-6.
66. Mankoff DA, Shields AF, Krohn KA. PET imag-ing of cellular proliferation. Radiol Clin North Am 2005; 43: 153-67.
67. Yamamoto Y, Nishiyama Y, Kimura N, Ishi-kawa S, Okuda M, Bandoh S, Kanaji N, Asa-kura M, Ohkawa M. Comparison of (18) F-FLT PET and (18) F-FDG PET for preoperative stag-ing in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2008; 35: 236-45.
68. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor re-sponse to chemotherapy by 3'-deoxy-3'-[18F] fluorothymidine positron emission tomogra-phy: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005; 65: 4202-10.
69. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44: 1426-31.
70. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA. Evalua-tion of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006; 129: 393-401.
71. 18F-α-methyl tyrosine PET. AJR Am J Roentgenol 2010; 195: 1204-11.